| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |